Login / Signup

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Debbie G J RobbrechtChristiane JungelsMorten Mau SorensenIben SpanggaardFerry EskensSigne Ø FretlandTormod Kyrre GurenPhilippe AftimosDavid LibergChrister SvedmanLars ThorssonNeeltje SteeghsAhmad Awada
Published in: British journal of cancer (2021)
NCT03267316.
Keyphrases
  • endothelial cells
  • binding protein
  • induced pluripotent stem cells
  • open label
  • small molecule
  • amino acid